Corbus Pharmaceuticals Completes Enrollment for Phase 1b Obesity Trial (CRB-913), Data Expected Summer 2026

summarizeSummary

Corbus Pharmaceuticals announced the completion of patient enrollment for its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity, with results anticipated in summer 2026.

check_boxKey Events

• Phase 1b Trial Enrollment Completed

  Corbus Pharmaceuticals announced the "Last Patient First Visit" in its CANYON-1 Phase 1b clinical trial for CRB-913 in obesity, indicating full patient enrollment.

• Data Readout Expected Summer 2026

  The 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants is on track to be completed in summer 2026.

• CRB-913 Targets Obesity with Novel Mechanism

  CRB-913 is a once-daily oral CB1 inverse agonist, offering a potentially differentiated approach to weight loss compared to existing incretin therapies.

• Builds on Positive Phase 1a Results

  Previous Phase 1a data showed a mean 2.9% placebo-adjusted weight loss by Day 14 and a favorable safety profile, including no significant GI or neuropsychiatric issues.

auto_awesomeAnalysis

This filing signals positive operational progress for Corbus Pharmaceuticals' lead obesity candidate, CRB-913. The completion of patient enrollment for the Phase 1b CANYON-1 study de-risks the trial timeline and sets the stage for a significant data readout in summer 2026. Given the large market for obesity treatments and the company's focus on a non-incretin approach, successful trial progression is a key value driver. Investors should monitor for the upcoming Phase 1b results, which will provide further insight into CRB-913's efficacy and safety profile, building on promising Phase 1a data.